Regulatory Blog

Next-generation sequencing (NGS) has become an essential tool in antiviral drug development, enabling detailed analysis of viral genetic changes and the identification of resistance-associated variants. Compared with traditional sequencing methods, NGS generates extensive sequence data that provides a deeper understanding of viral populations throughout clinical development. To promote consistent and high-quality regulatory submissions, the U.S. Food and Drug Administration (